hotspot -WSS

hotspot

author：leisure time 2025-08-23 23:20:17 - browse：476

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

hotspot

WSS

2 US Navy sailors arrested for allegedly spying for China

Violet CEO on training clinicians to promote more inclusive care

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

HCA sued by state AG for quality issues at Mission Health

OTC birth control: A brief history of over the counter pill design

The drug industry sees a key ally in the Senate prevail

leisure time

hotspot

focus

Guidelines to prevent youth baseball injuries need more muscle

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Hepatitis C has a cure — but many Americans still lack access to it

For BCIs, commercial hurdles may be bigger than scientific ones

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Drug repurposing or repositioning? The language matters

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

In Spain, a hospital brews its own CAR

Wikipedia

2 US Navy sailors arrested for allegedly spying for China

Christmas in the PICU brings some surprising joy

Violet CEO on training clinicians to promote more inclusive care

Dramatically reducing cancer deaths requires the PASTEUR Act

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Gilgo Beach: Police identify another victim in serial killing investigation

focus

hotspot

hotspot

entertainment